Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Final Medicare Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

The CMS coverage and analysis group has had to divert its attention from finishing a CED guidance to finalizing proposed changes to the process for awarding Medicare coverage for investigational device trials, primarily due to staff cuts, says Louis Jacques, who heads the group.


Related Content

Cohesive Coverage-With-Evidence Authority Needed For Medicare, Lawmakers Told
Reimbursement Briefs: Pfizer Joins Big Data Group; Part D Protected Classes; Wikipedia Partners With Cochrane Collaboration
CMS Proposes Noncoverage For Percutaneous Image-guided Lumbar Decompression
CMS Proposes Centralized Review, New Standards For Reimbursement Of IDE Studies
Device Makers Seek Clarity On CMS' Plans For Coverage With Evidence Development
CMS Ambiguous On Role Of Local Contractors In Coverage With Evidence Development
Medicare CED Could Enhance Efficiency Of FDA Post-Approval Studies – CMS Draft Guidance


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts